International dating agency cleopatra
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (m BC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. These data will be presented today in the Presidential Symposium at the European Society for Medical Oncology (ESMO) 2014 congress in Madrid, Spain (Abstract #350O_PR; Sunday, September 28, – p.m.CEST) and are also featured in the official ESMO Press Briefing.After Alexander’s death, Greek occupation of Alexandria lasted 300 years until the start of Cleopatra’s reign.Queen Cleopatra was a full-blooded Greek and a mighty Egyptian Pharaoh.Roche has developed three innovative medicines that have helped transform the treatment of HER2-positive breast cancer: Herceptin, Perjeta and Kadcyla.
The Perjeta regimen has also been granted accelerated approval as a neoadjuvant treatment (use before surgery) for HER2-positive early breast cancer (e BC) by the U. CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) was an international, Phase III, randomised, double-blind, placebo-controlled study.
Secondary endpoints included OS and safety profile.
An interim OS analysis from the CLEOPATRA study was previously presented at the San Antonio Breast Cancer Symposium (SABCS) 2012.
In 2013, the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs.
Genentech, in the United States, is a wholly owned member of the Roche Group. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).